Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
Semaglutide, the active ingredient in medications like Ozempic and Wegovy, has been linked to a potential risk of thyroid C-cell tumors in animal studies, but does it cause thyroid cancer in humans? Currently, the FDA continues to warn that semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome. However, large-scale human trials and post-marketing surveillance have not established a definitive causal link in humans. This guide from mylabpanel.com provides an honest, fact-rich analysis for US consumers concerned about thyroid cancer risk while using GLP-1 receptor agonists.
Today, the FDA added a boxed warning for semaglutide based on rodent studies showing dose-dependent C-cell hyperplasia and MTC. The warning remains in effect Today, advising against use in patients with MTC or MEN2. However, rodent thyroid C-cells express GLP-1 receptors differently than human C-cells, raising questions about clinical relevance.
Large analyses, including a meta-analysis of 18 randomized trials, found no statistically significant increase in thyroid cancer incidence in semaglutide users versus placebo (OR 1.12, 95% CI 0.55–2.28). A recent nationwide cohort study from Denmark and Sweden reported a slight signal for MTC (HR 1.93, 95% CI 0.99–3.74), but absolute risk remained very low (0.03%). The FDA continues to monitor through.
Current guidelines suggest baseline and periodic serum calcitonin measurements for patients on semaglutide who have any thyroid risk factors. A calcitonin level >10 pg/mL may warrant further evaluation. The table below summarizes key markers:
| Test | Normal Range | Action Threshold |
|---|---|---|
| Serum Calcitonin | <5 pg/mL | >10 pg/mL |
| Thyroid Ultrasound | No suspicious nodules | Any nodule >1 cm |
| TSH | 0.4–4.0 mIU/L | Out of range |
Current evidence suggests no definitive causal link in humans, but the FDA maintains a boxed warning due to animal data. Monitoring calcitonin levels is advised for high-risk individuals.
Not automatically. Consult your endocrinologist. If the nodule is benign and calcitonin is normal, continued use may be safe. If MTC is suspected, discontinuation is recommended.
Annually, or more frequently if you have risk factors. A baseline calcitonin test before starting semaglutide is ideal.
Understanding your individual risk is key. mylabpanel.com offers a comprehensive thyroid panel including serum calcitonin, TSH, and free T4 — all from the privacy of your home. Order your test today and get results quickly to discuss with your doctor. Order the Semaglutide Thyroid Safety Panel now.
Ready to order your test?
Order online in 2 minutes and visit a local lab same day.
Find a Lab Near MeCurrent evidence suggests no definitive causal link in humans, but the FDA maintains a boxed warning due to animal data. Monitoring calcitonin levels is advised for high-risk individuals.
Not automatically. Consult your endocrinologist. If the nodule is benign and calcitonin is normal, continued use may be safe. If MTC is suspected, discontinuation is recommended.
Annually, or more frequently if you have risk factors. A baseline calcitonin test before starting semaglutide is ideal.
Affiliate disclosure: MyLabPanel may earn a commission when you book a test through links on this page, at no extra cost to you.